147 related articles for article (PubMed ID: 36498511)
21. PRAME expression in 155 cases of metastatic melanoma.
Gradecki SE; Slingluff CL; Gru AA
J Cutan Pathol; 2021 Apr; 48(4):479-485. PubMed ID: 32939793
[TBL] [Abstract][Full Text] [Related]
22. PRAME Expression in Junctional Melanocytic Proliferations of the Conjunctiva: A Potential Biomarker for Primary Acquired Melanosis/Conjunctival Melanocytic Intraepithelial Lesions.
Huang YY; Hrycaj SM; Chan MP; Stagner AM; Patel RM; Bresler SC
Am J Dermatopathol; 2022 Oct; 44(10):734-740. PubMed ID: 35475786
[TBL] [Abstract][Full Text] [Related]
23. PRAME immunohistochemistry is useful in the diagnosis of oral malignant melanoma.
Hovander D; Allen J; Oda D; Moshiri AS
Oral Oncol; 2022 Jan; 124():105500. PubMed ID: 34452831
[TBL] [Abstract][Full Text] [Related]
24. PRAME expression in melanocytic lesions of the conjunctiva.
Šekoranja D; Hawlina G; Pižem J
Histopathology; 2021 Dec; 79(6):989-996. PubMed ID: 34268800
[TBL] [Abstract][Full Text] [Related]
25. PRAME Expression in Melanocytic Tumors.
Lezcano C; Jungbluth AA; Nehal KS; Hollmann TJ; Busam KJ
Am J Surg Pathol; 2018 Nov; 42(11):1456-1465. PubMed ID: 30045064
[TBL] [Abstract][Full Text] [Related]
26. Performance of PRAME immunohistochemistry compared with that of c-Kit, c-Myc, or cyclin D1 for the diagnosis of acral melanocytic tumors.
Jung JM; Lee MY; Won CH; Chang SE; Lee MW; Lee WJ
Pathol Int; 2023 Jan; 73(1):27-36. PubMed ID: 36468840
[TBL] [Abstract][Full Text] [Related]
27. PRAME is a useful marker for the differential diagnosis of melanocytic tumours and histological mimics.
Chen YP; Zhang WW; Qiu YT; Ke LF; Chen H; Chen G
Histopathology; 2023 Jan; 82(2):285-295. PubMed ID: 36200756
[TBL] [Abstract][Full Text] [Related]
28. Preferentially expressed antigen in melanoma immunohistochemistry as an adjunct for differential diagnosis in acral lentiginous melanoma and acral nevi.
Hu J; Cai X; Lv JJ; Wan XC; Zeng XY; Feng ML; Dai B; Kong YY
Hum Pathol; 2022 Feb; 120():9-17. PubMed ID: 34800527
[TBL] [Abstract][Full Text] [Related]
29. PRAME Immunohistochemistry as an Ancillary Test for the Assessment of Melanocytic Lesions.
Lezcano C; Jungbluth AA; Busam KJ
Surg Pathol Clin; 2021 Jun; 14(2):165-175. PubMed ID: 34023098
[TBL] [Abstract][Full Text] [Related]
30. PRAME expression in cellular neurothekeoma: A study of 11 cases.
Cesinaro AM; Piana S; Paganelli A; Pedroni G; Santandrea G; Maiorana A
J Cutan Pathol; 2022 Apr; 49(4):338-342. PubMed ID: 34761425
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic utility of PRAME in distinguishing proliferative nodules from melanoma in giant congenital melanocytic nevi.
Gill P; Prieto VG; Austin MT; Giubellino A; Torres-Cabala CA
J Cutan Pathol; 2021 Nov; 48(11):1410-1415. PubMed ID: 34164835
[TBL] [Abstract][Full Text] [Related]
32. PRAME immunohistochemistry is useful in the evaluation of conjunctival melanomas, nevi, and primary acquired melanosis.
LeBlanc RE; Miller DM; Zegans ME
J Cutan Pathol; 2021 Dec; 48(12):1442-1448. PubMed ID: 34089198
[TBL] [Abstract][Full Text] [Related]
33. Cyclin D1 and PRAME expression in distinguishing melanoma in situ from benign melanocytic proliferation of the nail unit.
Kim YJ; Jung CJ; Na H; Lee WJ; Chang SE; Lee MW; Park CS; Lim Y; Won CH
Diagn Pathol; 2022 Apr; 17(1):41. PubMed ID: 35484605
[TBL] [Abstract][Full Text] [Related]
34. PRAME immunohistochemistry for melanoma diagnosis: A STARD-compliant diagnostic accuracy study.
O'Connor MK; Dai H; Fraga GR
J Cutan Pathol; 2022 Sep; 49(9):780-786. PubMed ID: 35672262
[TBL] [Abstract][Full Text] [Related]
35. PRAME Is an Effective Tool for the Diagnosis of Nevus-Associated Cutaneous Melanoma.
Ronchi A; Cazzato G; Ingravallo G; D'Abbronzo G; Argenziano G; Moscarella E; Brancaccio G; Franco R
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254769
[TBL] [Abstract][Full Text] [Related]
36. The utility of PRAME staining in identifying malignant transformation of melanocytic nevi.
Lohman ME; Steen AJ; Grekin RC; North JP
J Cutan Pathol; 2021 Jul; 48(7):856-862. PubMed ID: 33433032
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic utility of PRAME expression by immunohistochemistry in subungual and non-subungual acral melanocytic lesions.
Rothrock AT; Torres-Cabala CA; Milton DR; Cho WC; Nagarajan P; Vanderbeck K; Curry JL; Ivan D; Prieto VG; Aung PP
J Cutan Pathol; 2022 Oct; 49(10):859-867. PubMed ID: 35794643
[TBL] [Abstract][Full Text] [Related]
38. The utility of PRAME immunohistochemistry in the evaluation of challenging melanocytic tumors.
Alomari AK; Tharp AW; Umphress B; Kowal RP
J Cutan Pathol; 2021 Sep; 48(9):1115-1123. PubMed ID: 33660310
[TBL] [Abstract][Full Text] [Related]
39. Aberrant expression of HMB45 and negative PRAME expression in halo nevi.
Ruby KN; Li Z; Yan S
J Cutan Pathol; 2021 Apr; 48(4):519-525. PubMed ID: 33184871
[TBL] [Abstract][Full Text] [Related]
40. PRAME immunohistochemistry of spitzoid neoplasms.
Koh SS; Lau SK; Scapa JV; Cassarino DS
J Cutan Pathol; 2022 Aug; 49(8):709-716. PubMed ID: 35488519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
